Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline.
- 1 cites
KDIGO 2026 guidelines recommend intravenous iron over oral iron and ESA as the first-line treatment for anemia in CKD, with a target hemoglobin below 11.5 g/dL.
- Why it matters: Effective management of anemia in CKD is crucial to improve patient outcomes, but optimal treatment strategies and thresholds remain uncertain, necessitating updated, evidence-based guidance.
- What they did: An international team reviewed evidence through 2024, grading recommendations using GRADE, and incorporated stakeholder feedback to develop 8 key graded recommendations and 49 practice points.
- The result: The guidelines enable personalized anemia treatment in CKD, emphasizing iron therapy thresholds, first-line use of ESAs, and individualized hemoglobin targets, supporting better clinical decision-making.